GSK hits go on pivotal TIM-3 lung cancer trial after phase 2 clears bar for advancement

GSK hits go on pivotal TIM-3 lung cancer trial after phase 2 clears bar for advancement

Source: 
Fierce Biotech
snippet: 

GSK’s anti-TIM-3 antibody is moving into a pivotal trial after hitting the mark in the midphase portion of the study, cementing the Big Pharma’s status as a front-runner in a thinning field featuring Novartis.